90 related articles for article (PubMed ID: 8893157)
1. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3.
Gómez E; de Oña M; Aguado S; Tejada F; Nuñez M; Portal C; Diaz-Corte C; Sanchez E; Ortega F; Alvarez-Grande J
Nephron; 1996; 74(2):367-72. PubMed ID: 8893157
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
Hibberd PL; Tolkoff-Rubin NE; Cosimi AB; Schooley RT; Isaacson D; Doran M; Delvecchio A; Delmonico FL; Auchincloss H; Rubin RH
Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
[TBL] [Abstract][Full Text] [Related]
4. CMV in kidney transplantation: a single center experience over 22 years.
Nashan B; Lück R; Kliem V; Brunkhorst R; Schlitt HJ; Klempnauer J
Clin Transpl; 1999; ():181-8. PubMed ID: 11038636
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
[No Abstract] [Full Text] [Related]
6. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
7. Is the incidence of cytomegalovirus disease following heart transplantation decreased by prophylactic ganciclovir and CMV-hyperimmunglobulin?
Cantarovich M; René P; Latter D
Transpl Int; 1994; 7 Suppl 1():S385-8. PubMed ID: 11271260
[TBL] [Abstract][Full Text] [Related]
8. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
Winston DJ; Imagawa DK; Holt CD; Kaldas F; Shaked A; Busuttil RW
Transplantation; 1995 Dec; 60(11):1357-60. PubMed ID: 8525537
[TBL] [Abstract][Full Text] [Related]
9. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
[TBL] [Abstract][Full Text] [Related]
10. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.
Aguado JM; Gomez-Sanchez MA; Lumbreras C; Delgado J; Lizasoain M; Otero JR; Rufilanchas JJ; Noriega AR
Antimicrob Agents Chemother; 1995 Jul; 39(7):1643-5. PubMed ID: 7492123
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus infection after renal transplantation: selective prophylaxis and treatment.
Pascual J; Alarcón MC; Marcén R; Burgos FJ; Tato A; Tenorio MT; Liaño F; Ortuño J
Transplant Proc; 2003 Aug; 35(5):1756-7. PubMed ID: 12962783
[TBL] [Abstract][Full Text] [Related]
13. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
[TBL] [Abstract][Full Text] [Related]
14. Impact of OKT3 and polyclonal antibodies on symptomatic CMV infection in renal transplant recipients.
Yeung S; Tong KL; Chan HW
Transplant Proc; 2000 Nov; 32(7):1928-9. PubMed ID: 11120005
[No Abstract] [Full Text] [Related]
15. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.
Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK
Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir prophylaxis of cytomegalovirus disease.
Conti DJ; Shen G; Singh T; Isenberg A; Freed BM
Transplant Proc; 1997; 29(1-2):804-6. PubMed ID: 9123534
[No Abstract] [Full Text] [Related]
19. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
[TBL] [Abstract][Full Text] [Related]
20. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay.
Cirocco RE; Ciancio G; Esquenazi V; Burke GW; Miller J
Transplant Proc; 1999; 31(1-2):1362-3. PubMed ID: 10083604
[No Abstract] [Full Text] [Related]
[Next] [New Search]
